Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.
However, people with liver cirrhosis remain at risk and should continue screening even after being cured.
Left untreated, hepatitis C can lead to cirrhosis, liver cancer and the need for a liver transplant.
People who developed hepatocellular carcinoma after being cured of HCV had cirrhosis and worse liver function.
Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.
The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.
Barriers still stand in the way of making treatment available to all who need it.
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.
Study results underline the importance of treating hepatitis C virus.
Successful treatment with direct-acting antivirals prolonged survival by 18 months.
Those diagnosed with liver cancer after an HCV cure had a 66% lower risk of death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.